Norbert Bischofberger’s Kronos Bio has filed to raise up to $100 million in a Nasdaq IPO. The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line acute myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback